Agilent Technologies - Q4 2024

Executive Summary

• Q4 FY24 revenue $1.701B grew 0.8% reported (core -0.3%) and non-GAAP EPS $1.46 rose 6% YoY; both revenue and EPS exceeded the company’s prior Q4 guidance high end ($1.691B; $1.42), driven by continued stabilization and execution amid a gradual recovery.
• Segment mix: CrossLab services remained the growth engine (+5% YoY revenue; 32.6% op margin), while LSAG (-1%) and DGG (-1% reported, -3% core) were roughly flat; company book-to-bill >1 again, including instruments, signaling ongoing demand recovery into FY25.
• FY25 outlook: revenue $6.79–$6.87B (core +2.5%–3.5%), non-GAAP EPS $5.54–$5.61; management expects 50–70 bps operating margin expansion, modest 1H and normalization in 2H; Q1 FY25 guided to $1.65–$1.68B and $1.25–$1.28 EPS, with Lunar New Year timing a ~2pt YoY headwind.
• Strategic catalysts: new market-focused organizational structure announced, launch of Infinity III LC series to catalyze the LC replacement cycle, BIOVECTRA acquisition broadens CDMO exposure; dividend raised 5% to $0.248 per share.

What Went Well and What Went Wrong

• What Went Well

  • CrossLab outperformed: revenue +5% YoY to $426M with 32.6% op margin; contracts grew double digits and ACG grew in all regions except flat in China, underscoring resilience of recurring revenue and services attach rates.
  • Demand indicators improved: total company and instruments book-to-bill >1; instrument orders grew YoY for the first time in 2024, suggesting steady recovery into FY25.
  • Diagnostics strength pockets: pathology grew high single digits in Q4; genomics returned to low single-digit growth with Magnis automated NGS traction, improving DGG’s mix quality.
  • Strategic actions: organizational realignment to market-focused groups intended to accelerate innovation and customer closeness; Infinity III LC launched with strong early orders; BIOVECTRA closed, expanding CDMO modalities (peptides, gene-editing support).

• What Went Wrong

  • Instruments still constrained: LSAG revenue fell 1% YoY as conservative CapEx weighed; gross margin fell 70 bps YoY to 55.1% on lower volume/mix.
  • DGG softness areas: despite pathology strength, expected NASD and cell analysis instrument softness pressured DGG; DGG -3% core in Q4.
  • Americas and China mixed: China revenue down 3% YoY (but sequentially improved) and Americas pressured by NASD; stimulus timing still uncertain in FY25 phasing.

Transcript

Operator (participant)

Thank you. Parmeet Ahuja, you may begin your conference.

Parmeet Ahuja (VP of Investor Relations)

Thank you, and welcome everyone to Agilent's conference call for the fourth quarter of fiscal year 2024. I'm sure you've seen our press release earlier today regarding our new market-focused organizational structure, which we will talk about in more detail. These changes have no impact on our company's consolidated financial statements. All financial metrics and guidance during this call will be shared under our historical structure. We will provide recast historical segment information to reflect these changes ahead of our upcoming Investor Day. Now, on to our quarterly results. With me are Padraig McDonnell, Agilent President and CEO, and Bob McMahon, Agilent Senior Vice President and CFO. Joining in the Q&A will be Phil Binns, President of the former Life Sciences and Applied Markets Group, Simon May, President of the newly formed Life Sciences and Diagnostics Markets Group, and Angelica Riemann, President of the Expanded Agilent CrossLab Group.

Also joining in the call is Mike Zhang, President of the newly formed Applied Markets Group. This presentation is being webcast live. The news release for our fourth quarter financial results, investor presentation, and information to supplement today's discussion, along with the recording of this webcast, are available on our website at www.investor.agilent.com. Today's comments will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year, and references to revenue growth are on a core basis. Core revenue growth excludes the impact of currency in any acquisitions and divestitures completed within the past 12 months. Guidance is based on forecasted exchange rates. During this call, we will also make forward-looking statements about the financial performance of the company.

These statements are subject to risks and uncertainties and are only valid as of today. The company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risks and other factors. And now, I'd like to turn the call over to Padraig.

Padraig McDonnell (CEO and President)

Great. Thank you, Parmeet. Hello everyone, and thank you for joining today's call. Before I begin, I would like to welcome new AMG President Mike Zhang. While Mike is new to this role, he is not new to Agilent. Mike joined Agilent more than 20 years ago as a manufacturing engineer in China and most recently was Vice President and General Manager of the GC and GCMS business within our former Life Sciences and Applied Markets Group. With his broad experience in both manufacturing and in the business, Mike will be an incredible asset in this role. I'm very much looking forward to him moving AMG and Agilent forward. I also want to take a moment to wish Phil Binns a wonderful retirement in advance of him leaving Agilent. Phil joined Agilent with the Varian acquisition in 2010.

All told, Phil is celebrating just over 40 years of service with Agilent and Varian. Although Phil is retiring from the business president role, he has graciously agreed to serve as a special advisor through April 2025. All of us at Agilent wish Phil the very best and look forward to working with him during the last five months at Agilent. Now, on to our high-level Q4 results. I'm happy to share not only our solid fourth quarter results that point to continued steady market recovery, but also our outlook and drivers for 2025 fiscal year. I'm especially excited to talk about Agilent's customer-first strategy evolution and our aggressive transformation ambition that led to the news you read ahead of the call, a new market-focused organizational structure to become a nimbler, even more customer-centric company to accelerate our performance.

In the fourth quarter, the Agilent team delivered revenue of $1.701 billion, roughly 1% reported growth with a flat core growth. This represents a sequential improvement of over 400 basis points from Q3. In addition, our total company book-to-bill was greater than one. This points to a steady market improvement we're seeing, and we expect it to continue in 2025. We also gained share in all our geographies, evidence that even in challenging CapEx environments, customers trust Agilent. As we evolve, we are confident this will only accelerate. Bob will provide deeper details on our Q4 results and our outlook for Q1 and FY25. Now, I'd like to spend some time talking about our new organizational structure we announced earlier today. Our new market-focused organizational structure is a result of our customer-centric market-first strategy and an important step in our organizational transformation work, which we have named Ignite.

This is a product of our enterprise-focused strategy that drives our evolution to become a nimbler, even more customer-centric company to accelerate our performance. The new market-focused organizational structure is one of the most significant changes Agilent has seen in a decade and continues the work we did creating our commercial organization three years ago. The commercial organization doubled down on our customer-first approach in the field and is a critical competitive advantage in supporting our customers. At that time, we started by creating a singular commercial leadership structure. We then created a foundational infrastructure and intensified our focus on digital capabilities, accelerated an end-to-end customer experience, and ensured sales channels were customer and market-centric. So, the changes you see today are part of the successful journey we started three years ago.

With the new structure, we are aligning business units to our markets, facilitating close collaboration among the businesses like never before, and enabling better execution on cross-division customer-first priorities. We are combining the strengths of our three businesses as well as our portfolios so that we can offer end-to-end solutions and workflows that revolve around our customers and markets. The Life Sciences and Diagnostics Markets Group, or LDG, represents $2.5 billion in annual revenue and is primarily focused on our pharma, biopharma, and clinical diagnostics end markets. LDG provides a comprehensive portfolio of leading technology platforms and solutions to serve Agilent's customers' value chain, including research and discovery, development and scale-up, production of therapeutics, and development of critical cancer diagnostics. LDG includes LC and LC/MS cell analysis, as well as CDMO capabilities, which include NASD and BIOVECTRA. The business also includes pathology, companion diagnostics, and genomics.

Simon May will serve as President of LDG. Prior to joining Agilent earlier this year, Simon was Executive Vice President and President of Life Science Group at Bio-Rad Laboratories. The Applied Markets Group, or AMG, represents $1.3 billion in annual revenue and is focused on food, environmental, forensics, chemicals, and advanced materials markets. AMG includes GC and GCMS, spectroscopy, vacuum technology platforms, and certified pre-owned business. AMG will focus on growing Agilent's strong leadership in these markets and accelerating growth in new areas of the market. Mike Zhang, a 22-year veteran of Agilent, has been promoted to President of AMG. Most recently, Mike was Vice President and General Manager of our GC and GC/MS product lines, and the Agilent CrossLab Group, or ACG, represents $2.7 billion in annual revenue and is focused on supporting our customers in all our end markets.

The group is uniquely positioned to leverage its comprehensive portfolio and capabilities to further enhance the install base of instruments with targeted workflows and applications that drive critical outcomes and productivity in labs. ACG includes services, software, and informatics, automation, and consumables. This business will accelerate and strengthen customer relationships across all end markets. Angelica Riemann, a 25-year veteran of Agilent, will continue to serve as President of ACG. Prior to her current role, she served as Vice President and General Manager of the ACG services business. This change is one of the many that demonstrate how we're becoming nimbler and accelerating the pace of innovation. You can see that with the Q4 launch of the exciting Agilent Infinity III LC series that harnesses our 50 years of LC expertise and leadership.

The Infinity III series has advanced automation that simplifies our customers' daily routines and is compatible with the previous generations, which allows for seamless upgrades and technology refreshes, and Agilent InfinityLab LC solutions are certified by My Green Lab. These instruments optimize lab space, and they reduce water, solvent, and energy consumption while also minimizing waste. While just launched in October, early traction from customers has been very positive. Also in Q4, we closed our acquisition of BIOVECTRA, demonstrating our commitment to providing customers the most advanced capabilities to accelerate their therapeutic programs. With BIOVECTRA now being part of Agilent, we expand our portfolio of CDMO services beyond our market-leading oligonucleotide production at NASD. We're adding more rapidly growing therapeutic modalities like peptide synthesis, a market expected to continue to expand rapidly over the coming years, and bringing world-class capabilities to support gene editing therapies.

Just last month, my leadership team and I visited BIOVECTRA to welcome our new team members to Agilent, and we became even more exhilarated by the capabilities we would be able to harness. Plus, both Agilent and BIOVECTRA’s focus on putting customers first and accelerating the pace of innovation so we can add to and capitalize on opportunities was abundantly clear as I spoke to dozens of BIOVECTRA employees. Separately, during the quarter, we hit another important milestone. For the full year, we passed the $1 billion mark in digital orders for the first time across the company. This is a result of our investment in our digital ecosystem to ensure our customers can do business with us in ways that meet their needs. To reinforce what I've stated in previous calls, we're sharply focused on key growth factors such as biopharma, PFAS, and advanced materials.

The Agilent team is mobilized to accelerate value creation through our Ignite transformation program. The objective of Ignite is to drive revenue growth and margin expansion by increasing our execution capabilities. The world is moving faster than ever, and so are we. That's exactly why we introduced our new market-focused organizational structure. We are laser-focused on winning in the marketplace and adding value to our customers and shareholders. We will dive more deeply into these details, including our evolved strategy and the Ignite transformation that will help us execute on that strategy at our investor day on December 17th in New York. Bob will now provide the details of our results as well as our outlook for the fiscal year of 2025 and the fourth quarter. After Bob delivers his comments, I will be back for some closing remarks. Over to you, Bob.

Bob McMahon (SVP and CFO)

Thank you, Padraig, and good afternoon, everyone. In my remarks today, I will provide some additional details on fourth quarter revenue and take you through the income statement and other key financial metrics. I'll then cover our guidance for fiscal year 2025 and the first quarter of 2025. Unless otherwise noted, my remarks will focus on non-GAAP results. As Padraig said, we are pleased with our Q4 results. Agilent finished the fourth quarter with core growth in line with our expectations, while EPS exceeded our expectations as we executed well against a challenging, albeit improving, market. Q4 revenue was $1.701 billion, a decline of 0.3% core, but a sequential improvement of over 400 basis points. On a reported basis, our revenues were up 0.8% as we benefited from 50 basis points of currency, and BIOVECTRA contributed 60 basis points.

Looking at our Q4 performance by business unit, the Life Sciences and Applied Markets Group reported $833 million in revenue. That represents a 1% decline as instrument volumes continue to be constrained by conservative customer CapEx spending, while consumables grew mid-single digits. Having said that, for our instruments business, our orders grew year-on-year, and for the third consecutive quarter, our book-to-bill was once again greater than one. We see this as positive evidence of an ongoing steady instrument recovery. Moving on to Agilent CrossLab Group, the business delivered revenue of $426 million for the quarter, up 5%. ACG grew in every market and in every region except China, where it was flat year-over-year, but up sequentially. The contracts business, including our fast-growing enterprise services business, grew double digits again in Q4 as it has every quarter this year.

Our largest customers continue to maximize utilization of their assets, right-size their operations, and leverage OpEx budgets to deliver on their productivity goals and outcomes. We recently received a top supplier award from one of our largest strategic customers in the applied markets as a recognition of our longstanding and beneficial partnership throughout the years. The Diagnostics and Genomics Group posted $442 million in revenue, representing a 3% decline that was slightly above expectations. Pathology saw solid growth globally and was offset by expected softness in NASD and cell analysis instruments. Now, looking at our end markets and geographies, our largest end market, pharma, declined 1%, slightly better than what we expected. Within pharma, biopharma declined mid-single digits, while small molecule grew low single digits. Encouragingly, all regions, except for the Americas, grew in the quarter. The Americas region was pressured by the expected decline of NASD.

We expect both the Americas region and NASD to return to growth in fiscal year 2025. In chemicals and advanced materials, revenue grew 1%, with our advanced materials sub-market growing mid-single digits, driven by our business in the semiconductor market. Our business in the diagnostics and clinical end market performed strongly, growing 7%, driven by pathology and improved performance in genomics. In environmental and forensics, we declined 6%, although dollars were roughly flat sequentially. All regions grew, except for the U.S., related to timing of orders. That being said, we continue to see very strong growth in PFAS solutions, with our business growing more than 40% in Q4 across multiple end markets. Now, wrapping up our end markets, food was down 3% versus last year, while our academia and government market was down 1%.

Geographically, Asia ex-China grew high single digits, and Europe grew low single digits in the quarter, while the Americas and China declined as expected. China was down only 3% and exceeded our expectations. We also booked our first China stimulus orders in October and anticipate much more in fiscal year 2025. Now, let's move to the rest of the P&L. Gross margin was 55.1% in the quarter, down 70 basis points versus last year, driven by lower volume and mix. Our operating margin was 27.4%, as our productivity initiatives and the cost actions we took earlier in the year were fully recognized this quarter. The annualization of these savings, coupled with the market recovery and the initial returns from the Ignite transformation, give us confidence in driving EPS growth in fiscal year 2025. In addition, we continue to look for ways to drive EPS growth below the line.

Our net interest income was in line, while we benefited from a lower tax rate in the quarter, and our share count was 287 million diluted shares outstanding. Now, putting it all together, Q4 earnings per share was $1.46. That was ahead of our expectations and up 6% from a year ago. Now, let me turn to cash flow and the balance sheet. We continue to enjoy a very strong balance sheet and healthy cash flows. Operating cash flow was $481 million in the quarter, and we invested $93 million in capital expenditures. For the year, we well exceeded our operating cash flow expectations, with operating cash flow of $1.75 billion. During the quarter, we returned over $400 million to shareholders, consisting of $335 million in share repurchases and $68 million in dividends. For the year, we returned over $1.4 billion to shareholders through repurchasing shares and dividends.

Looking forward, you may have also seen recently we announced a 5% increase in our quarterly dividend, marking another year of increases in advancing our industry-leading dividend yield. We ended the quarter with a net leverage ratio of 1.1, a very strong number even as we acquired BIOVECTRA in the quarter. Our strong cash flow and healthy balance sheet provide us with plenty of opportunity to invest in the business going forward. In summary, we performed well and saw steady market improvement in the quarter. We are executing well, staying disciplined, and investing in high-growth opportunities. Now, let's move on to our outlook for the upcoming fiscal year and first quarter. We expect the recovery that we have seen the past few quarters to continue throughout fiscal 2025.

While we expect the market to grow slower than historical rates for the full year, we expect improvement throughout the year, with the second half of the year returning to more traditional levels of growth. We expect our results to mirror that cadence of improvement on a core basis. As Padraig noted earlier, we exited Q4 with a book-to-bill ratio over one for the company and greater than one for instruments. In addition, Q4 was the first quarter in 2024 that instrument orders grew year-on-year. While one quarter does not a trend make, it is certainly encouraging. For the full-year guide, we expect revenue in the range of $6.79 billion-$6.87 billion. This represents a reported growth range of 4.3%-5.5%. Currency is a slight headwind of 0.2 points, while M&A related to BIOVECTRA contributes 2% at the low end and 2.2% at the high end.

This translates to a core growth of 2.5% to 3.5%. To start the year, we think this is a prudent way to plan given the near-term dynamics in the U.S. From a geographic perspective, we expect modest growth in the Americas and Europe. While we see funnel activity increasing in China, we're taking a conservative approach on the timing of revenue associated with the stimulus. We expect to see recovery over the course of the year in China, resulting in slightly positive growth for the full year. From a business group perspective, we expect to return to growth in all three groups led by ACG. As a note, this statement is true under the new structure as well. As Parmeet mentioned earlier, we will provide recast historical segment information to reflect these changes ahead of our upcoming investor day.

In terms of phasing, we expect improvement throughout the year, with more normalized growth expected in the second half of the year. We are projecting roughly 50 to 70 basis points of operating margin expansion for the year. Below the line, we expect net interest expense of $25 million due to the financing of BIOVECTRA versus the net interest income this year. In addition, we expect a tax rate of 13% and 286 million shares outstanding. Fiscal 2025 non-GAAP EPS is expected to be in the range of $5.54-$5.61 and incorporates the planned $0.05 year-one dilution from BIOVECTRA. This range represents a 5%-6% growth rate, and if excluding the BIOVECTRA dilution, a growth rate of 6%-7% year-on-year. We expect cash flow to remain strong in fiscal year 2025.

We are expecting roughly $1.65 billion in operating cash flow and $450 million in CapEx as 2025 is the peak spending year for the NASD expansion. Looking to Q1, we expect revenue in the range of $1.65 billion-$1.68 billion. Our forecast assumes no significant budget flush during the end of this calendar year. This represents a reported decline of 0.5% to growth of 1.3%. Currencies are 30 basis points headwind, while M&A is expected to contribute 1.8 points of growth. We are expecting core growth between a decline of 2% to flat at the upper end. It's important to note that we estimate our projected Q1 year-over-year results will be negatively impacted this year by roughly 2 percentage points due to timing of the Lunar New Year, which occurs in late January versus February of last year.

This includes the additional $15 million in revenue pull forward we communicated in Q1 of last year. Adjusting for the Lunar New Year impact, we are expecting continued sequential growth improvement. First quarter 2025 Non-GAAP earnings per share are expected to be between $1.25 and $1.28, lower than the full-year growth rate due to the Lunar New Year timing. Looking into 2025 and beyond, we remain incredibly optimistic about the future of our markets and our long-term prospects. We are confident in our new market-focused approach, and the Ignite transformation will propel us to accelerated growth, and we will become a stronger company. With that, I'll turn it back over to Padraig for some closing comments. Padraig?

Padraig McDonnell (CEO and President)

I've said it before, and I want to say it again. These are exciting times at Agilent.

Over the last several months, we've been focused on evolving our strategy, transforming our processes, and empowering our people while continuing to win in the marketplace. Already, we've made bold moves that have created momentum. We've developed our future strategy. We've kicked off our Ignite transformation to help execute on that strategy, and along the way, we've made moves to create new growth vectors. We are making acquisitions that will contribute to our growth, and we are strengthening our capability to efficiently and effectively integrate those acquisitions that will lay the foundation for future M&A. These initial actions position us well for the journey ahead. They ensure we are building the capability, strength, and speed to reinvigorate our culture and enable us to thrive while delivering outstanding results for our customers and for our shareholders.

But amid all this change, Fortune magazine this month named Agilent number 11 among the world's best workplaces 2024, a list that only includes 25 companies. This is yet another recognition of what we already know internally: the Agilent team is the best in the industry. This is not only a recognition of our outstanding company culture, but of the talented professionals we have, ones who are ambitious, resilient, and high-performing. This is exactly the team we need to evolve Agilent, to build an enduring company that sets the standard for excellence with our customers and creates value for our shareholders. Thank you again for joining today's call. I couldn't be more energized by the momentum we have, the opportunities we will seize, and the history we will make. Now, I look forward to answering your questions. Parmeet?

Parmeet Ahuja (VP of Investor Relations)

Thanks, Padraig. Operator, if you could please provide instructions for Q&A now.

Operator (participant)

At this time, I would like to remind everyone, in order to ask a question, press star, then the number one on your telephone keypad. We'll pause for just a moment to compile the Q&A roster. And your first question today comes from the line of Patrick Donnelly from Citi. Your line is open.

Patrick Donnelly (Managing Director)

Hey, guys. Thanks so much for taking the questions. Padraig, maybe one for you just on the instrument side. I know you guys touched on the book-to-bill, over one for three quarters now, a little bit of instrument growth on the order side year-over-year. Can you just talk about where we are in the cycle, what your expectations are? As you guys know, there's a debate in the market about what the cycle looks like. Does it overcorrect to the upside as we work our way through the next year or so?

How are you guys framing that up? What's the right way to think about this replacement cycle, where we are, and the size of it as we go forward here?

Padraig McDonnell (CEO and President)

Yeah, thanks, Patrick. Great question. So clearly, we're seeing a steady recovery in instruments, and our book-to-bill was greater than one, which is really great to see in terms of replacement cycle. But what you would see across the industry is that it's not uniform. It's across different vendors. It's at different speeds and, of course, at different times. But what we do see is that we're probably midway through the expected timing on where we expect that replacement cycle to be. We see competitors are probably benefiting from a refresh of their own installed base with some new systems. But what you would see from our side is our Infinity III that we announced last month.

We expect to start seeing an increased demand for our solutions, and we're seeing a lot of excitement with our customer base, and we've already seen tens of millions of dollars in orders there, so what we expect in that replacement cycle is to be slow and steady, but really kicking off in Q1.

Patrick Donnelly (Managing Director)

Okay, and that's helpful, and then maybe on China, always a focus with you guys. It sounds like slight growth for 2025 is the right way to think about it. Can you just talk about what you guys are seeing there and hearing there? Bob, helpful to hear that you guys got your first stimulus orders there in October. What's the expectation as we move forward here? It sounds like a steady recovery. Are you still seeing, I know you guys were kind of hovering around that $300 million revenue a quarter stability.

So it sounds like continued and maybe a little bit of improvement as we work our way through the year. Are there different segments that are maybe picking up a little bit? It would be helpful to talk through that. Thank you, guys.

Padraig McDonnell (CEO and President)

Yeah. Yeah, thanks, Patrick. So performance was a bit better than expected, and it was also really encouraging to see lab activity to continue to improve across our services and consumables. So we actually have seen quite dramatic share gains within China, which is also a really good point. So what I would say is it's steadily improving, talking to the teams. And I would say on the stimulus side, we talked in the call about we've already had some stimulus orders in. We expect much more in Q1. That will, of course, translate to revenue.

This is a really, really good sign as we see momentum, both from the direct input of more confidence in the market and, of course, getting the dollars in. Steadily improving. We expect that through the year, Patrick. We expect as we go through the stimulus orders and we go forward, expect that to improve. One area that was a real standout for us was PFAS in China. It was the fastest-growing business for us across the globe, our region across the globe. That just goes to show the durable nature of some of these growth vectors that are happening, where you have the Emergent Pollutants Act moving. What we've seen in China is that our great technical expertise coupled with our great solutions are ready there to pick up the business. That was one real clear standout.

Bob McMahon (SVP and CFO)

Yeah.

Hey, Patrick, just want to add on to what Padraig is saying. You're absolutely right. We ended the quarter with roughly $310 million, $312 million to be precise in China, which was a nice sequential increase from Q3, and it was down 3%, as I mentioned. In addition to the PFAS, both chemical and advanced materials actually grew in the quarter where we have a leadership position, and pharma was flat, which was actually a very nice thing, and we're taking a kind of a conservative approach, as I mentioned, in terms of the stimulus orders, but we are seeing quite an active funnel from the standpoint of bidding activity here in the first half of this quarter, as well as and expect that to continue throughout the course of 2025.

Patrick Donnelly (Managing Director)

Okay. That's helpful. Thanks, Bob and Padraig. I appreciate it.

Padraig McDonnell (CEO and President)

Thanks, Patrick.

Operator (participant)

Your next question comes from a line of Matt Sykes from Goldman Sachs. Your line is open.

Matt Sykes (Research Analyst)

Hi, good afternoon. Thanks for taking my questions. Maybe the first one just on DGG, which has been sort of weighing on growth over the course of the year, but noticeably a strong quarter. You had called out cancer DX as well as genomics. Could you just provide a little bit more color on what's driving that growth and how sustainable do you think that growth is, particularly in genomics as we move through 2025?

Padraig McDonnell (CEO and President)

Yeah. I'll just start off, and I'll kick it over to Simon. We really are seeing nice growth in our pathology business, which grew high single digits in Q4 and is slightly ahead of expectations. A highly durable business in any market.

What we're seeing in genomics, while it's a still challenging market, we posted low single-digit growth, which was also ahead of expectations. But Simon, I don't know if you want to add some color.

Simon May (President of Life Sciences and Diagnostics Market Group)

Yeah, just a couple of quick points to add as Padraig mentioned. We were pretty pleased with the high single-digit growth that we saw in pathology in the quarter. And in particular, the blend and the mix between instruments and consumables there. We continue to be really healthy with our instrument placements, and we think that tees up quite nicely going into 2025. On the genomics side, it was really notable because it's the first time that we've seen growth in genomics for quite a while now.

I'd say we've had a bit of a pivot in our strategy there to really double down on the growth drivers that we see in genomics, where we've got clearly differentiated value propositions. And in particular, our Magnis automated NGS library prep continues to see fantastic traction. We're also very encouraged by the pipeline that we're seeing for our Avida NGS chemistry. And again, this gives us a lot of hope going into FY 2025. And as I think about both pathology and genomics and these growth factors that we see here, we do believe that they're durable given the macro conditions and the competitive position that we enjoy.

Matt Sykes (Research Analyst)

Great. Thanks. And maybe just for my follow-up, a high-level question for you, Padraig, on the resegmentation. It makes sense from a go-to-market strategy for some of these segments to put them together.

I'm wondering from an R&D development and new product innovation how this might help. I mean, you referenced the LC replacement cycle accelerating faster for competitors as they refresh their installed base. Should we start to see a faster cycle of new product introductions due to the re-segmentation, or is it going to be similar to the pace that we've seen in the past and re-segmentation really doesn't necessarily inform R&D direction?

Padraig McDonnell (CEO and President)

Yeah. Well, look, I think we're refocusing the groups really for a few reasons. We want to be closer to our customers, but also understanding where do we want to make our biggest investment or most asymmetric investments that are going to accelerate innovation in key areas, and when I talk about focus, it's really three things. It's the energy and time, but also the capital allocation.

And what you will see from this refocusing of our segments, we're going to be able to do that. You're going to see programs accelerate. But also, we don't want to be two inches deep across the company. We want to be focused on our key growth factors and making sure we accelerate. We have a huge amount of product lines. And of course, we can have incremental additions to product lines across the board. But from this new structure, you're going to see an acceleration of R&D, no doubt about it.

Matt Sykes (Research Analyst)

Thank you.

Operator (participant)

Your next question comes from a line of Rachel Vatnsdal from JPMorgan. Your line is open.

Rachel Vatnsdal (Executive Director)

Perfect. Thank you for taking the questions, you guys, and good afternoon. So I wanted to follow up on Patrick's question on China.

appreciate that it's early days, but how are you guys thinking about the risk of potential tariff impact on Agilent's business at this point in China and in the rest of the world? Is there anything embedded in guidance currently from a tariff standpoint? And then can you remind us, what was the tariff impact to Agilent from the first Trump administration?

Bob McMahon (SVP and CFO)

Yeah. Hey, Rachel, this is Bob. I'll take that question. As you can imagine, there's been a fair amount of work that we've been doing on this exact question. What I would take it, if I took it into two chunks, actually, we've been working on diversifying our supply chain, particularly within China, back in 2018-2019 when the first tariffs came and then obviously doubled down on that resiliency with COVID. And so it is $10 million-$15 million existing today.

And we think that the future potential magnitude of this is certainly manageable with us with additional mitigation activities. Obviously, with something that would be more broad-based than that, it would be more material. But to just give you a frame of reference, roughly 2/3 of our business in the U.S. comes from a product that's sourced in the U.S.

Rachel Vatnsdal (Executive Director)

Great. That's helpful. And then just for my follow-up, you mentioned that chemical and advanced materials grew 1% this quarter. I was wondering, could you just break down some of the trends that you saw within that? You mentioned that semiconductors drove some of the performance that you saw on the advanced materials side. You actually had one of your peers call out some weakness in semis this quarter. So just talk to us about what you're seeing from an underlying perspective on that side.

And then again, just on the industrial business as well. Thanks.

Padraig McDonnell (CEO and President)

Yeah. So in the chemical and advanced materials, we grew 1%, and we saw 4% in materials. And that's driven a lot by the battery business that we have and, of course, semiconductor. We saw a slight decline in chemical and energy. But overall, we're very happy with the growth that we've seen in Asia ex-China. By the way, it was driven and also low single digits in China. So the one thing that I would note about this industry is that we've got the broadest platform and solutions around it. And CAM is returning to positive year-on-year growth for the first time since Q2 in 2023. So that really bodes well for the future.

Bob McMahon (SVP and CFO)

Yeah. Hey, Rachel, and maybe just for the benefit of you and the rest of the folks on the call, I talked about guidance.

If you look at it by end market, just to kind of give everyone a frame, for the full year, FY 2025, we're expecting pharma to return to growth. So low to mid single-digit growth there. Academia and government roughly flat. Actually expect the diagnostics and clinical that Simon just talked about to continue and be the highest growth end market, at least to start off the year here in FY 2025 at mid single digits. CAM also low to mid, given the work and the discussion that Padraig just gave. And then food and environmental, both low single digits with pockets of very strong growth. And really, food, there was a potential where that actually could accelerate throughout the course of the year, given some of the potential changes in the administration coming up.

Operator (participant)

Your next question comes from a line of Vijay Kumar from Evercore ISI. Your line is open.

Vijay Kumar (Senior Managing Director)

Hey, guys. Thanks for taking my question. Maybe, Bob, off of the last question here on the drivers of fiscal 2025, when you look at the first half versus second half, it does assume a back half step up. I'm just curious, is that being driven by end markets normalizing? Maybe if you could just walk us through from first half versus back half dynamics in fiscal 2025.

Bob McMahon (SVP and CFO)

Yeah, Vijay, that's exactly right. So obviously, our first quarter is what I would call artificially depressed just because of the nature of our timing of our fiscal year relative to Lunar New Year. But if you looked at first half versus second half, we're expecting this continued recovery throughout the course of the year and with a more normalized growth in the back half of the year. And so where does that show up?

It shows up in a couple of areas. Obviously, with the potential for China getting better throughout the course of the year, as Padraig mentioned, certainly stimulus can help that. We've taken a conservative approach on that and not fully baked in with all the activity that we talked about. We'll see how that plays out, but certainly, early days are very positive from that standpoint and then also from a pharma perspective, we're also expecting to see that recovery, particularly on the back of Infinity III, as Padraig just mentioned, and that replacement cycle accelerating so you're actually seeing those would be the two biggest and then continued biotech recovery on the small biotech side as well throughout the course of next year.

Vijay Kumar (Senior Managing Director)

Understood and then one on maybe margins free cash flow side. Pretty impressive free cash execution in fiscal 2024.

I just want to make sure I had the numbers right. Is the guide assuming a free cash step down, Bob? Is that a timing element? And on the margins, sort of similar cadence question. What is Q1 assuming and what drives the back half step up in margins? Thank you.

Bob McMahon (SVP and CFO)

Yeah. So Q1, so let me answer your question around free cash flow. Yeah, we are expecting a slight slip down really as a result of a step up in CapEx spending this year versus last year as we finished the heavy levels of spending for the NASD expansion for Train C and D. I don't expect that to continue into 2026 and 2027. So you would see that then step back down. So that free cash flow is really a timing issue.

In terms of Q1 profitability, with the lower revenue, we typically have higher expenses in Q1 as some of the merit resets. We've got our sales meetings and kickoff meetings there, and then you've got some January, typically is a very light month, but we have a full amount of expenses in there, and then you then also look at the Ignite transformation that Padraig talked about. Many of those activities that we've been kicking off will come into play in the second half of the year, which will generate incremental savings both on the top line and the bottom line, and you'll hear more about that, some of those details at the investor day in mid-December.

Vijay Kumar (Senior Managing Director)

Understood. Thank you.

Operator (participant)

Your next question comes from a line of Jack Meehan from Nephron Research. Your line is open.

Jack Meehan (Equity Research Analyst)

Thank you. Good afternoon.

Bob, I was wondering if you could just walk us through for the 2025 guide what this assumes for each of the segments. Not sure if you can provide it under the old method or just the new method, but any color would be great.

Bob McMahon (SVP and CFO)

Yeah, I could do that. So if you think about this at, I'll call it legacy numbers. So LSAG, kind of low single digits with the consumables business being kind of mid single digits and slower on the instrument throughout the course of the year. That's probably our area where we've taken a prudent approach as we go through the course of the year. It could be more than that depending on the uptake of the replacement cycle for Infinity III. But low single digits there.

ACG continue to be very strong with mid to high single-digits as the instrumentation recovery and then continued double-digit on the services business just continues to be a real stalwart of growth, and we still have a lot of opportunity there around connect rate, and then for DGG, kind of low- to mid-single-digit growth going forward, which is a recovery, the continued performance of pathology and the genomics business, as Simon mentioned, and then a return to growth really for NASD.

Jack Meehan (Equity Research Analyst)

Great. Okay, and then I was wondering if you could just talk a little bit more just what your expectations are for LC, LC/MS. I think everybody's trying to benchmark expectations for next year, and one of your peers sounds a little bit more bullish as it pertains to the cycles.

I don't know if you have any thoughts as we try and compare and contrast some of these results. Any color would be great. And maybe just off of that, any comments you can share around GLP-1 contribution? I think that might be a factor, but any color would be great. Thank you.

Padraig McDonnell (CEO and President)

Yeah. So there's a lot of dynamism in terms of replacement cycle. It doesn't happen at any time, as I said before, any one time, but it's across the board in different industries and different times. From our perspective, our LC and LC/MS orders are improving. There's no doubt about that. And we have a huge amount of excitement around our Infinity III. We have a lot of focus programs with our customers around that. So what you will see next year is, I think, a steady increase in cadence of that replacement cycle.

It's a little bit too early to call. Will that be gradual over a number of quarters or a bolus in one quarter, maybe then a slowdown and again on the next quarter, but we're really watching that as we go forward. I think we're being very conservative around what we're seeing on that because of a lot of turbulence as everybody has seen in the last few years in the market, but I would say customer sentiment is steadily improving, and on the GLP-1 side, we had a really fantastic year. We grew 30% in GLP-1 this year. We're involved in a lot of new site buildouts in QA, QC departments and actual getting closer to production as well with systems, so a very, very, very strong year.

Actually, one thing that's really interesting is through the acquisition of BIOVECTRA, who of course have a healthy pipeline of GLP-1 and synthetic peptides within their CDMO capability. We're seeing a lot of requests from both sides of the business about how we can help customers both on the analytical side and on the CDMO side. So we're seeing a huge amount of synergies there. So this is a market that's going to continue very strongly, and we're going to be really there to take the business.

Bob McMahon (SVP and CFO)

Hey, Jack, just to build on what Padraig is saying on the LC replacement cycle, I think one of the things is we're taking a more conservative approach, as Padraig mentioned. I think if that happens, we will get that business, rest assured.

I would also say if we look at the age of our installed base, it is continuing to get old. It is probably well beyond the median now and throughout the course of next year. So we would expect that to continue to be able to be replaced because when we look at the instrumentation through our consumables business and our services business, the activity continues to be there. So these instruments are being used. And so it's only a matter of time to be able to do that replacement.

Jack Meehan (Equity Research Analyst)

Awesome. Thank you, guys.

Operator (participant)

Your next question comes from a line of Dan Leonard from UBS. Your line is open.

Dan Leonard (Managing Director and Research Analyst)

Hi. Thank you. Just to clarify on instruments one last time, is your expectation that instrument growth is flat in 2025 in aggregate across all platforms?

Bob McMahon (SVP and CFO)

Our expectation that it will grow. Low single digits, Dan.

Dan Leonard (Managing Director and Research Analyst)

Okay.

Then my follow-up, you mentioned, I think, something about the administration and changes in your food forecasts. Are there any other areas where you think the change in U.S. administration, any other areas that you were sensitive to when putting together your forecast for 2025?

Padraig McDonnell (CEO and President)

Yeah. Look, there's a lot of changes that can happen at this time. There's a lot of people expecting a lot of change. We have yet to see what those changes will be. Of course, you can see maybe some changes in the NIH funding, which is very low for us as a percentage of the business. We actually expect the PFAS spending will actually increase as it goes forward on it. The area to watch, I would say, is, of course, tariffs, which Bob talked about. We're ready for that, ready for any scenario on that side.

But also on biopharma, I think, is the IRA is also continues to move forward. The International Pricing Index, seeing what happens on biopharma is going to be really important. So that's why we're taking a kind of conservative, prudent approach. So lots going on. But what I would say is from the strategy work, we're ready for all outcomes.

Dan Leonard (Managing Director and Research Analyst)

Okay. Thank you.

Operator (participant)

Your next question comes from a line of Puneet Souda from Leerink Partners. Your line is open.

Puneet Souda (Senior Managing Director)

Yeah. Hi, Padraig. Bob, thanks for taking my questions. First one, just wanted to clarify on the tariff side. I mean, if there were any retaliatory tariffs, could you elaborate on your manufacturing and final assembly positions just globally so we can understand sort of how much of the product is sort of China for China, made in China versus made in other Asian countries and not coming from U.S.?

Padraig McDonnell (CEO and President)

Yeah. Maybe I can start off by talking about our U.S. supply chain in there. About 60%, as Bob said, is produced in the United States. About 35% is the rest of the world. So it's actually a small percentage that's produced in China. But of course, we have mitigations and step there. We have many supply chain areas across the globe that we can move around. And we've done that before since 2018. We expect the impact probably in a quarter of $4 million-$5 million. We can probably mitigate that within a few months. So I would say we're waiting to see how that all plays out, but we're already taking steps across potential tariffs. The big question for everybody is, will it be beyond China? I think everybody's waiting to see what that is. But even in that case, we're ready with mitigations.

Bob McMahon (SVP and CFO)

Yeah.

Hey, Puneet, to build on what Padraig is saying, particularly for retaliatory tariffs in China, very little of our revenue now is produced in the U.S. that goes into China. We've spent a lot of time and effort building in China for China, and we have a full portfolio of capabilities there, which is actually really important for us to be able to take full advantage of the stimulus products today. So I think that that number will be relatively small from the standpoint of retaliatory impact from China exports from the U.S.

Puneet Souda (Senior Managing Director)

That's helpful. Thanks. And then I have a question on Infinity III series. Just wondering, given the launch timing, was there any pause that you saw on the instrumentation and the ordering side prior to October? And what is the order book telling you? Do you think this is what's driving?

Is it a major driver of instrumentation orders in the quarter being positive, as you pointed out?

Padraig McDonnell (CEO and President)

Yeah. We had a minimal effect, to be honest. We really planned around that. And of course, we are very careful with our customers to make sure we bring them through the cycle of replacement. So minimal impact. We're very extremely excited about it. It's a system that not only will be best in class in terms of performance, but also in terms of productivity. And that's what we're hearing loud and clear from our customers. It's about productivity and how it lends their labs to be more productive going forward. We're extremely pleased with the order book that we've seen so far. And we expect that that will continue to ramp. And customers are really voting with their orders on that. So we're excited about that ramp for next year.

Puneet Souda (Senior Managing Director)

Okay.

Bob McMahon (SVP and CFO)

Thank you. Look forward to the investor day.

Operator (participant)

Your next question comes from a line of Tycho Peterson from Jefferies. Your line is open.

Tycho Peterson (Managing Director)

Hey, thanks. I want to probe in pharma a little bit. Are you able to delineate what LC did and what mass spec did in the quarter? And then just thinking a little bit about the new administration, I know you're not guiding for any budget flush here, but is there any risk of kind of a pause in spending given all the moving pieces around pharma? What are you hearing from customers at this point?

Padraig McDonnell (CEO and President)

Yeah. Maybe I can start with the second part, Tycho. We're not seeing a pause from pharma. If anything, we're actually seeing a little bit more activity. So we're not seeing that across the board. And that's about the U.S. and globally.

And of course, that's something we really want to watch with the new administration coming in and what transpires over the next few weeks. But in terms of the LC and LC/MS, Bob, I don't know if you have any color on that.

Bob McMahon (SVP and CFO)

Yeah. Yeah. Hey, Tycho, just to give you a couple of different kind of pieces of data. If I look at our pharma business overall, it was down low single digits. Pharma, small molecule was actually up 3% overall with biotech or biopharma being down. If we look at specifically LC, LC/MS within pharma, it was up low single digits.

Tycho Peterson (Managing Director)

Okay. That's helpful. And then the follow-up on NASD, I know I think you're talking about back to growth in 2025. Can you maybe just talk a little bit about your ability to cross-sell with BIOVECTRA and then how you're thinking about clinical versus commercial customers?

Padraig McDonnell (CEO and President)

Yeah.

I'll start off, Tycho, and I'll hand it over to Simon. First of all, we are extremely pleased on the cross-selling ability between the two businesses. It was one key source of value about why we did the BIOVECTRA acquisition that customers were asking us for this capability, a broader range of capability, and we've seen that actually accelerate from both sides. Simon, I don't know if you want to add more color on NASD.

Simon May (President of Life Sciences and Diagnostics Market Group)

Yeah. Just to build on what Padraig said with BIOVECTRA and the NASD cross-pollination, there's been really strong engagement between the teams. In fact, they spent several days together in our Boulder facility last week. I'd say they came away really energized that the portfolio complementarity fit between the businesses is exactly as we expected, in fact, maybe a little bit more so.

Then as we think about NASD going into FY 2025, I think as Bob mentioned earlier, we're projecting high single-digit growth for the business. The order book looks really strong in NASD, but it's important to understand the nuances of the mix in that order book. We've got a number of commercialization qualifications going on right now. So in terms of FY 2025 revenue, there's a lot of energy going into that with relatively limited revenue upside. And a lot of that's going to actually hit towards FY 2026. But again, the order book overall is very healthy. And as we think about 12, 18, 24 months view, we're really bullish about what we're seeing. But once again, high single-digit growth. Maybe we'll nudge double-digit in NASD in FY 2025.

Tycho Peterson (Managing Director)

Thank you.

Operator (participant)

Your next question comes from a line of Brandon Couillard from Wells Fargo. Your line is open.

Brandon Couillard (Managing Director)

Hey, thanks. Good afternoon.

Just on the Infinity III launch, can you remind us when the Infinity II, I think it was the 1290 system rolled out? And is there an ASP premium? Is there an ASP kicker to this replacement cycle this time as well in terms of the 3 versus the legacy 2 system? Thanks.

Padraig McDonnell (CEO and President)

Yeah. We don't talk about a difference in pricing on it. But I think we've had a number of years, of course, very, very successful years with the Infinity II. And this builds on the success. I will say that the install base for Agilent is way broader than the Infinity II. We have 1100s that are very, very prominent out there. We have a lot of labs with 1100s. And those are the labs first, I think, that are going to be talking about replacement.

But we also have seen significant interest from Infinity II customers because the CD extra productivity capability is really going to help them in the lab. So I would say it's not just one series to the next. It's a broad installed base replenishment cycle we're going to see.

Bob McMahon (SVP and CFO)

Yeah. All I would say is pricing has held up very nicely. Early days.

Brandon Couillard (Managing Director)

Okay. And then Mike or excuse me, Mike. Bob, how much of the CapEx in next year is tied to the Train B and C build-out for NASD? We expect those to come online. And what does maintenance CapEx look like in fiscal 2026? Thanks.

Bob McMahon (SVP and CFO)

Yeah. That's a great question. So roughly half is NASD between the continued build-out and the validation activities of that 450.

If I look at kind of maintenance CapEx, think about it in kind of 2.5x to 3x sales range on a go-forward basis. That's total [audio distortion].Thank you.

Operator (participant)

Your next question comes from a line of Doug Schenkel from Wolfe Research. Your line is open.

Doug Schenkel (Managing Director)

Good afternoon, guys. Thanks for taking my questions. I just want to start first with a question on guidance philosophy. Just to be clear, it sounds like you're trying to factor in a degree of conservatism on China-based, China stimulus, the impact of uncertainty as it relates to the new administration, conservatism on a potential LC replacement cycle. Hopefully, I'm not missing anything there. But is it fair to say that error bars around your assumptions are wider than normal heading into a new fiscal year?

And your intent across the board was to make assumptions that were consistently on the lower end of those error bars?

Padraig McDonnell (CEO and President)

I think you said it well. We were very conservative in that because of those reasons. What is the expected LC replacement cycle recovery? Is it faster? Is it a little bit less than that? The China stimulus, which is very early days, I think we want to make sure that we continue to monitor that. And of course, whether we see improved conditions or not in terms of sentiment in the U.S. So all of these things are factoring into this. So it is conservative in what we're guiding. But also, I'd say the bars are wider than normal.

Doug Schenkel (Managing Director)

Okay. Thank you for that.

And just as always, correct me if I'm wrong, but I believe in your prepared remarks, you indicated that small molecule was up low single digits while biopharma was down mid-singles. If I have that right, is that comp effect, or are you seeing more of a recovery in demand among small versus large molecule applications? And I guess finally, if so, why? That seems to be a little contradictory to what we've heard from some others. So just curious if you could give us a little more there.

Bob McMahon (SVP and CFO)

Yeah, Doug, no, you heard it right. Our small molecule business was up low single digits across both instruments. It was the combination of instruments and services. And our biotech, our large molecule was down mid-singles. Now, if you took out NASD, which shows up in the large molecule, it was down low single-digits.

Better recovery than the mid single-digits. And it actually speaks to, I think, that continuation of volume in small molecule. If you look at pill count, it continues to go up. And these are well-capitalized companies. They have probably the older fleet when you just think about kind of the replacement versus kind of the biotechs of the world. And so we're expecting that to continue. And it was the first to kind of come down. And so we're in the cycle. And I think we're expecting it to be the first moving positive. Now, we think there's more upside in biotech than there is in small molecule, but it certainly is a nice leading indicator around the idea around this replacement cycle.

Doug Schenkel (Managing Director)

Okay. Thanks very much.

Operator (participant)

Your next question comes from a line of Michael Ryskin from Bank of America. Your line is open.

Michael Ryskin (Managing Director)

Great.

Thanks for taking the question, guys. First, I want to ask a quick follow-up on China stimulus. I know you just kind of touched on it in a couple of different questions. But early in the prepared remarks, you did make some comments of seeing some initial China stimulus orders come in. I think China in the quarter exceeded your expectations. I know there's not a lot embedded directly into the guide, but could you just walk us through sort of how China stimulus could play out next year? And I'm asking this from a perspective of gradual ramp as you go through the year. Is it sort of going to be a trickle? Could it be very back-end loaded? Just trying to think through the various scenarios and what you're looking for there once these initial orders clear.

Padraig McDonnell (CEO and President)

Yeah.

Look, I think what we've seen is that it's much broader, this stimulus in terms of range. We spoke about that before. We see it both on commercial and government accounts. Our first orders have actually come in from government accounts. We've been highly successful in those overall tenders, and we're in the low millions range, low single-digit millions range of orders that are in. We're expecting to close much more this quarter. And one thing that's really playing into our favor is our broad platform capabilities, including the technical capabilities of our teams up and running. And you couple that with our Made in China initiatives that we've really invested over the last year. It puts us in a very, very strong position to capitalize. But it'll be interesting to see how that's launched.

Past the first quarter, we don't have great visibility yet, but of course, a lot of deal activity, but the first quarter is looking very strong in terms of orders.

Bob McMahon (SVP and CFO)

Yeah. Hey, Mike, and just to kind of frame in kind of how we're thinking about China, to your point, if we took Q4 and just divided by or multiplied by four, that would get you to that low single-digit growth. Now, we're expecting a recovery throughout the course of the year, but that kind of gives you a sense for what we put in the initial guide, and we'll know a lot more about the timing of the stimulus revenues going forward once we actually get those awarded and then the delivery dates and so forth, but we do think that that will occur throughout the course of the year.

Michael Ryskin (Managing Director)

Okay. That's helpful.

Then, Bob, maybe for you, just on the margin guide for next year, 50-70 basis points, it's a really impressive starting point, honestly, better than I think a lot expected, especially given still a little bit of a subdued top-line environment. How much of that can you attribute to Ignite and maybe some part of the transformation or one-time cost savings? How much is just the underlying strength of business, maybe with tied to price or some mix shift next year? Just a little bit of what's going into that margin expansion for next year.

Bob McMahon (SVP and CFO)

Yeah. What I would say, Mike, is it's a little of all those things. So maybe stay tuned, and we'll give you a little more meat on the bones here come mid-December. But we certainly have some incremental opportunities both in price and cost efficiencies associated with the Ignite transformation.

Those things will start to feather into the second half of this year, as I mentioned before. If you recall, the first half of this year also has the annualization of the savings of the actions that we had to take in the June-July timeframe as well. We're benefiting from that in the first half. That somewhat gets anniversaried. Then you also have the merit increases and so forth that gets reset. So you'll actually see this throughout the course of the year through a series of initiatives that have already been kicked off, so.

Padraig McDonnell (CEO and President)

I would say, just following off of that, Bob, we're very excited to meet everybody in December in New York to talk about it. It's an extremely well-thought-out program. It's across the board.

And it's ultimately going to help us to invest for growth in key areas as well as margin expansion. So stay tuned.

Michael Ryskin (Managing Director)

Okay. Thanks a lot, guys.

Operator (participant)

And your final question comes from a line of Dan Brennan from TD Cowen. Your line is open.

Dan Brennan (Senior Equity Research Analyst)

Great. Thanks for taking the questions here. Maybe the first one just on pharma in the Americas. I think you called that in the prepared remarks. Americas pharma ex-NASD was kind of maybe a weaker spot. Can you just unpack a little bit what's happening in the US versus, say, Europe, rest of the world, and kind of what's kind of assumed from what happened in 4Q in the 2025?

Padraig McDonnell (CEO and President)

Yeah. I mean, look, we saw a lot of strength in Europe in terms of pharma. I wouldn't read too much into the American numbers.

I think there is, of course, companies wondering about their CapEx budgets, and that comes at different phases. But we expect pharma to continue next year in the growth rates that Bob laid out in terms of our guide.

Dan Brennan (Senior Equity Research Analyst)

Okay. That's helpful. And then maybe just one on if I can just go into the broader market. I know you talked about the prepared remarks, Bob, and a few times it came up like you're expecting a below-trend market, at least. It sounds like for the first half of the year. Can you just remind us in terms of your kind of growth algorithm maybe? What are your assumptions based upon for market growth typically? Kind of what are you assuming? And kind of specifically, is it just pharma that's weaker, or are there other spots that you're pointing to that are below trend?

Any color on that would be helpful.Thank you.

Bob McMahon (SVP and CFO)

Yeah, Dan, if we looked at the long-term growth rates of our markets, we believe those are in mid single-digits, four to six. When you look at the aggregate across, we're obviously not expecting that for the full year here. We are expecting that we're doing better than the market. If you look at kind of how we exited here, roughly flat on a core basis, if you adjust for the timing of Lunar New Year, you're at the midpoint, 1%, and expect that kind of performance to continue that cadence. And so you would have the second half of the year, a more normalized kind of growth rates. And so it's really across the board. We're seeing some of the industrial or applied markets, things like CAM, being a little ahead of the curve.

Certainly, our diagnostics and clinical business continues to be strong. It has been throughout the course of this year, exiting at a very healthy rate, and I would expect that to continue. The big ones are pharma coming in and then some of the other applied markets as well, so.

Operator (participant)

This concludes the question and answer session. Mr. Ahuja, I turn the call back over to you.

Parmeet Ahuja (VP of Investor Relations)

Thanks, Rob, and thanks everyone for joining the call today. Before we sign off, I'd like to wish everyone a happy Thanksgiving. Have a good rest of the day and week, everyone.

Operator (participant)

This concludes today's conference call. You may now disconnect.